These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33593235)

  • 41. Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population.
    Yu XY; Zhao Y; Song XX; Song ZY
    J Zhejiang Univ Sci B; 2014 Oct; 15(10):879-87. PubMed ID: 25294377
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care.
    Caballeria L; Augustin S; Broquetas T; Morillas RM; Vergara M; Virolés S; Hernández MR; Serra I; Goday A; Vila L; Siso-Almirall A; Solans R; Fernández-Real JM; Carrión JA; Graupera I; Ginès P
    Med Clin (Barc); 2019 Aug; 153(4):169-177. PubMed ID: 31178295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonalcoholic fatty liver disease and cardiovascular disease.
    Liu H; Lu HY
    World J Gastroenterol; 2014 Jul; 20(26):8407-15. PubMed ID: 25024598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.
    Haflidadottir S; Jonasson JG; Norland H; Einarsdottir SO; Kleiner DE; Lund SH; Björnsson ES
    BMC Gastroenterol; 2014 Sep; 14():166. PubMed ID: 25260964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonalcoholic Fatty Liver Disease and Liver Transplantation.
    Pham T; Dick TB; Charlton MR
    Clin Liver Dis; 2016 May; 20(2):403-17. PubMed ID: 27063277
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.
    Younossi ZM
    Liver Transpl; 2018 Feb; 24(2):166-170. PubMed ID: 29272073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis.
    Piazza NA; Singal AK
    Exp Clin Transplant; 2016 Feb; 14(1):79-85. PubMed ID: 26581602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management.
    Gracious BL; Bhatt R; Potter C
    J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):602-10. PubMed ID: 26447642
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study.
    Kempiński R; Łukawska A; Krzyżanowski F; Ślósarz D; Poniewierka E
    Adv Clin Exp Med; 2019 Dec; 28(12):1615-1620. PubMed ID: 31025557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.
    Leite NC; Villela-Nogueira CA; Cardoso CR; Salles GF
    World J Gastroenterol; 2014 Jul; 20(26):8377-92. PubMed ID: 25024596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.
    Chrysavgis L; Ztriva E; Protopapas A; Tziomalos K; Cholongitas E
    World J Gastroenterol; 2020 Nov; 26(42):6514-6528. PubMed ID: 33268944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges.
    Goldner D; Lavine JE
    Gastroenterology; 2020 May; 158(7):1967-1983.e1. PubMed ID: 32201176
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of patients with non-alcoholic steatohepatitis (NASH) in real life.
    Serfaty L
    Liver Int; 2018 Feb; 38 Suppl 1():52-55. PubMed ID: 29427486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Vassilatou E
    World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonalcoholic Fatty Liver Disease in Children.
    Mann JP; Valenti L; Scorletti E; Byrne CD; Nobili V
    Semin Liver Dis; 2018 Feb; 38(1):1-13. PubMed ID: 29471561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study.
    Swain MG; Ramji A; Patel K; Sebastiani G; Shaheen AA; Tam E; Marotta P; Elkhashab M; Bajaj HS; Estes C; Razavi H
    CMAJ Open; 2020; 8(2):E429-E436. PubMed ID: 32518095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study.
    Darbà J; Marsà A
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):877-881. PubMed ID: 35085473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.